Feedback
Settings

Settings

Goto Application

1. WO2026085716 - NEW IL-18 SUBSTITUTE AND USE THEREOF

Submit observation
PermaLink
Publication Number WO/2026/085716
Publication Date 30.04.2026
International Application No. PCT/CN2024/126480
International Filing Date 22.10.2024
IPC
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C12N 15/85 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 5/10 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12N 15/13 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
Applicants
  • 上海洛启生物医药技术有限公司 SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD. [CN]/[CN]
Inventors
  • 万亚坤 WAN, Yakun
  • 朱敏 ZHU, Min
Agents
  • 上海一平知识产权代理有限公司 XU & PARTNERS, LLC.
Priority Data
Publication Language Chinese (zh)
Filing Language Chinese (zh)
Designated States
Title
(EN) NEW IL-18 SUBSTITUTE AND USE THEREOF
(FR) NOUVEAU SUBSTITUT D'IL-18 ET SON UTILISATION
(ZH) 新型IL-18替代物及其用途
Abstract
(EN) Provided are a new IL-18 substitute and the use thereof. Specifically, provided is a class of nanobodies targeting an IL-18 receptor. The IL-18Rb nanobody and the IL-18Ra nanobody specifically bind to an IL-18Rb chain and IL-18Ra chain of an IL-18 receptor, respectively, and a bispecific antibody based on the two monospecific nanobodies can effectively stimulate PBMC to release IFNγ, and exhibit a significant and effective tumor inhibitory effect. Therefore, the provided antibody can be used as a therapeutic long-acting substitute factor for IL-18, and provides a new strategy for clinical disease treatment.
(FR) L'invention concerne un nouveau substitut d'IL-18 et son utilisation. Plus particulièrement, l'invention concerne une classe de nanocorps ciblant un récepteur d'IL-18. Le nanocorps anti-IL-18 Rb et le nanocorps anti-IL-18Ra se lient de manière spécifique à une chaîne d'IL-18Rb et une chaîne d'IL-18Ra d'un récepteur d'IL-18, respectivement, et un anticorps bispécifique basé sur les deux nanocorps monospécifiques peut stimuler efficacement le PBMC pour libérer l'IFNγ, et présenter un effet inhibiteur tumoral significatif et efficace. Par conséquent, l'anticorps fourni peut être utilisé en tant que facteur de substitution à action prolongée thérapeutique pour IL-18, et fournit une nouvelle stratégie pour le traitement d'une maladie clinique.
(ZH) 提供了新型IL-18替代物及其用途。具体地，提供了一类靶向IL-18受体的纳米抗体。所述IL-18Rb纳米抗体和IL-18Ra纳米抗体分别特异性结合IL-18受体的IL-18Rb链和IL-18Ra链，并且基于两种单特异性纳米抗体的双特异性抗体能够有效刺激PBMC释放IFNγ，且展现出显著有效的肿瘤抑制效果。因此，提供的抗体能够作为IL-18的治疗性长效替代因子，为临床疾病治疗提供新策略。

Latest bibliographic data on file with the International Bureau

The publication of an international application under the Patent Cooperation Treaty in PATENTSCOPE (which constitutes an element of the Gazette) does not imply the expression of any opinion whatsoever on the part of the International Bureau of WIPO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

# -